Am J Transplant, Volume 20, Suppl 3 Archives - Page 19 of 223 - ATC Abstracts

2020 American Transplant Congress
Evolution of Molecular Lung Transplant Biopsy Assessment: Rejection Can be Detected in Mucosal as Well as Transbronchial Biopsies
M. D. Parkes¹, K. Halloran², P. Halloran², &. the INTERLUNG Study Group³
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³., ., AB, Canada
*Purpose: We recently developed a Molecular Microscope® (MMDx) rejection assessment platform for mucosal biopsies from the third airway bifurcation (3BMB) and transbronchial biopsies (TBB) from…
2020 American Transplant Congress
The Impact of HLA-DQ Molecular Mismatches on De Novo Occurrence of Donor-Specific Anti-HLA Antibodies after Kidney Transplantation: An Observational Cohort Study
A. Senev¹, M. Coemans¹, V. Van Sandt², E. Van Loon¹, J. Callemeyn¹, B. Sprangers¹, D. Kuypers¹, M. Emonds¹, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²HILA, Red Cross-Flanders, Mechelen, Belgium
*Purpose: Evaluating HLA molecular mismatches (MM) instead of antigen mismatches might be a better tool to assess donor-recipient HLA incompatibility and provide a better risk…
2020 American Transplant Congress
Utilization of Kidneys from Deceased Donors with Positive Hepatitis C Nucleic Acid Amplification Testing (HCV NAT+)
K. L. King, S. A. Husain, S. Mohan
Columbia University, New York, NY
*Purpose: With modern direct-acting antiviral agents, transplantation of kidneys from HCV NAT+ deceased donors for recipients with or without HCV has expanded the kidney supply.…
2020 American Transplant Congress
Post-Operative Opiate Utilization and Prescribing Patterns in Living Kidney Donors
E. Calderon¹, D. S. Ubl², C. Jadlowiec¹, P. Dean³, E. Castle⁴, P. Andrews⁴, B. Taner⁵, E. Habermann², A. K. Mathur¹
¹Transplant Surgery, Mayo Clinic, Phoenix, AZ, ²Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, ³Transplant Surgery, Mayo Clinic, Rochester, MN, ⁴Department of Urology, Mayo Clinic, Phoenix, AZ, ⁵Transplant Surgery, Mayo Clinic, Jacksonville, FL
*Purpose: Living kidney donors (LKDs) become exposed to opioids during routine post-surgical care, which may lead to adverse outcomes. and since there is an absence…
2020 American Transplant Congress
Acute Rejection in Liver Transplant Recipients is a Rising Predictor of Death and Graft Failure in the Recent Era of Declining Hepatitis C Virus
T. Bittermann¹, D. S. Goldberg², J. Levitsky³
¹University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL, ³Northwestern University, Chicago, IL
*Purpose: Prior to 2013, hepatitis C virus (HCV) played a major role in liver transplant (LT) outcomes, and acute rejection (AR) was found to be…
2020 American Transplant Congress
Hepatitis C Antibody Seroconversion in Kidney Transplant Patients from HCV Antibody Positive/NAT Negative Donors Does Not Deteriorate Renal Allograft Outcome
R. Rattanavich, M. De Vera, T. Hoang, R. Villicana
Loma Linda University, Transplant Institute, San Bernadino, CA
*Purpose: Prior studies have shown that almost 50% of kidney transplant patients from hepatitis C Ab+/NAT - donors have seroconverted but its impact on renal…
2020 American Transplant Congress
Comparison of Outcomes between Patients Bridged to Heart Transplantation with ECMO versus Those Not Bridged with ECMO During the Years 1985 to 2019
D. J. Miklin¹, A. D. Salimbangon², G. S. Liu¹, P. Banankhah¹, P. A. Genyk¹, P. Kingsford¹, R. R. Chand³, J. P. Li¹, D. Vucicevic⁴, A. S. Vaidya¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, J. Nattiv¹, S. Hashmi¹, S. Nuno¹, J. Pizula¹, A. E. Lee¹, K. Yang¹, S. Shaw¹, E. DePasquale¹, W. M. Aaron⁵
¹LAC-USC, Los Angeles, CA, ²UCLA Medical Center, Los Angeles, CA, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴Newark Beth-Israel Medical Center, Newark, NJ, ⁵University of Arizona Sarver Heart Center, Tucson, AZ
*Purpose: Some patients with cardiogenic shock require extracorporeal membrane oxygenation (ECMO) for successful bridging to heart transplantation (HT). Herein, we report on the outcomes and…
2020 American Transplant Congress
10-Year Experience Transplanting Very Highly Sensitized Patients with End Stage Renal Disease
J. Diaz¹, J. Kennedy², S. Chinnakotla³, P. Verghese⁴
¹Department of Surgery, University of Minnesota, Saint Paul, MN, ²University of Minnesota, Minneapolis, MN, ³Department of Surgery, University of Minnesota, Minneapolis, MN, ⁴Department of Pediatrics, Division of Pediatric Nephrology, University of Minnesota, Minneapolis, MN
*Purpose: Very highly sensitized (VHS) individuals (calculated reactive antigen (cPRA) ≥ 95%) have increased rejection risk which negatively impacts kidney transplant outcomes. Multiple strategies have…
2020 American Transplant Congress
Gene Expression Dynamics Demonstrate Perturbations in Innate and Adaptive Immunity in Kidney Transplantation Patients with Cytomegalovirus Viremia
R. Ahn, J. Schaenman, Z. Qian, V. Groysberg, M. Rossetti, A. Hoffmann, D. Gjertson, M. Deng, E. F. Reed
University of California Los Angeles, Los Angeles, CA
*Purpose: Cytomegalovirus (CMV) viremia and disease continues to cause significant morbidity and mortality in kidney transplant patients with clinical complications including organ rejection and death.…
2020 American Transplant Congress
The Impact of a Positive Crossmatch on KAS Patients and Organs
J. Lee¹, K. Sjöholm², C. Kjellman², T. Lorant², L. Winstedt², V. Nigro², K. M. Roupé², Å. Schiött², A. Runstrom², S. Taranto³, T. Baker³, D. Stewart³
¹Medical Affairs, Hansa Biopharma, Camas, WA, ²Hansa Biopharma, Lund, Sweden, ³UNOS, Richmond, VA
*Purpose: Evaluate the potential effects of offer refusals due to positive crossmatch (+XM) on both patients and re-allocated organs with a focus on waitlist outcomes,…